This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Mylan generic schizophrenia drug infringes Janssen patent, US appeals court says

By Nick Robertson ( March 31, 2025, 13:56 GMT | Insight) -- Mylan Laboratories’ generic version of Janssen Pharmaceuticals’s schizophrenia medication Invega Trinza is likely to infringe a Janssen patent, the US Court of Appeals for the Federal Circuit affirmed Friday in a nonprecedential opinion. A three-judge panel held that Mylan’s label is likely to induce infringement and rejected the company’s doctor-patient divided infringement argument. The panel also held the Janssen patent not invalid.The US Court of Appeals for the Federal Circuit affirmed Friday that a Mylan Laboratories generic for the schizophrenia medication Invega Trinza is likely to induce healthcare providers to infringe a Janssen Pharmaceuticals patent, in a nonprecedential opinion. After finding the patent not invalid, a three-judge panel rejected Mylan’s divided infringement defense and label non-inducement argument....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections